Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Pancreatic ductal adenocarcinoma (PDAC) still presents a grim prognosis with less than 10% of newly diagnosed patients alive after 5-year, and by the end of 2030 PDAC is expected to become the second leading cause of cancer-related death in the United States [12]. Currently, only 15 –20% of patients are diagnosed with resectable disease and even with radical surgery 75% of them will recur within 5 years, supporting the idea of PDAC as a systemic disease since the onset. In metastatic or unresectable cancers, FOLFIRINOX and nab-paclitaxel plus gemcitabine regimens represent th e standard treatment, however offering a ...
Source: Cancer Treatment Reviews - July 22, 2021 Category: Cancer & Oncology Authors: Macchini Marina, Centonze Federico, Peretti Umberto, Orsi Giulia, Militello Anna Maria, Valente Maria Maddalena, Cascinu Stefano, Reni Michele Source Type: research

Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and Meta-analysis
Neuroendocrine tumors (NETs) are rare[1] and heterogeneous malignancies that are classified according to their site of origin, morphology, Ki-67 proliferation index, and mitotic count. An updated classification of the World Health Organization (WHO) of digestive neuroendocrine neoplasms (NENs) has been recently published and divides the NENs in neuroendocrine tumors (NET, grade [G]1, G2, G3), neuroendocrine carcinomas (NEC) and mixed non-neuroendocrine and endocrine malignancies (MiNEN)[2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 21, 2021 Category: Cancer & Oncology Authors: P. Trillo Aliaga, F. Spada, G. Peveri, V. Bagnardi, C. Fumagalli, A. Laffi, M. Rubino, L. Gervaso, E. Guerini Rocco, E. Pisa, G. Curigliano, N. Fazio Source Type: research

Uncommon and peculiar soft tissue sarcomas: multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II
In this second part of the “Uncommon and peculiar soft tissue sarcomas: multidisciplinary review and practical recommendations” from Spanish Group for Research on Sarcoma (GEIS –group), we will review, in a multidisciplinary way, another group of uncommon sarcoma subtypes, with the same objectives and rules we set up in the first part. We will analyze here the following subtypes: alveolar soft part sarcoma, epithelioid sarcoma, clear cell sarcoma, desmoplastic small round cell tumor, rhabdoid tumor, phyllodes tumor, tenosynovial giant cell tumors, myoepithelial tumor, perivascular epithelioid cell neoplas...
Source: Cancer Treatment Reviews - July 15, 2021 Category: Cancer & Oncology Authors: Javier Mart ínez-Trufero, Josefina Cruz Jurado, C. Nieves Hernández-León, Raquel Correa, Jose Manuel Asencio, Daniel Bernabeu, Rosa Alvarez, Nadia Hindi, Cristina Mata, Gloria Marquina, Virginia Martínez, Andres Redondo, Luis Javier Floría, M. Carmen Source Type: research

PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations
European Medicines Agency (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 14, 2021 Category: Cancer & Oncology Authors: H élène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, Susana Banerjee, Ana Oaknin, Domenica Lorusso, Isabelle Ray-Coquard Source Type: research

Uncommon and peculiar soft tissue sarcomas: multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish Group for Sarcoma Research (GEIS –GROUP). Part I
Soft Tissue Sarcomas (STS) is a heterogeneous and complex group of mesenchymal tumors with an annual incidence of 50-60 new cases per million people and year, which means about 1% of malignancies [1]. In the last WHO classification of Sarcomas, there are 64 locally aggressive and/or malignant subtypes, and this number is increasing, since new advances in molecular diagnosis have diversified and split up tumors into new diagnostic categories [2]. There are some subtypes with higher incidence like GIST, liposarcoma, leiomyosarcomas, and undifferentiated sarcomas, on which most of guidelines are focused, and which share someh...
Source: Cancer Treatment Reviews - July 10, 2021 Category: Cancer & Oncology Authors: Javier Mart ínez-Trufero, Josefina Cruz Jurado, M. Carmen Gómez-Mateo, Daniel Bernabeu, Luis Javier Floría, Javier Lavernia, Ana Sebio, Xavier García del Muro, Rosa Álvarez, Raquel Correa, C. Nieves Hernández-León, Gloria Marquina, Nadia Hindi, And Source Type: research

Repositioning PARP inhibitors in the treatment of thoracic malignancies
The evaluation of the homologous recombination repair (HRR) status is emerging as a predictive tumor agnostic biomarker for poly (ADP-ribose) polymerase (PARP) inhibition across different tumor types and testing for HRR-signature is currently a developing area with promising therapeutic implications. Treatment with PARP inhibitors (PARPi) either as single agent or in combination with chemotherapy have shown so far limited activity in patients with thoracic malignancies. A deeper understanding of the biological background underlying HRR-deficient tumors, along with the recent advent of new effective targeted and immunothera...
Source: Cancer Treatment Reviews - July 6, 2021 Category: Cancer & Oncology Authors: Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, Elena Parlagreco, Francesca Jacobs, Angela List ì, Luisella Righi, Paolo Bironzo, Silvia Novello, Giorgio Vittorio Scagliotti Source Type: research

Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis
Intrahepatic cholangiocarcinoma (iCC) has a rising incidence in Western countries [1]. Due to its relative rarity, treatment strategies utilising systemic therapies are mostly derived from the results of prospective trials including all biliary tract cancers (BTC) of different origins [2,3]. However, iCC might present a different biology and prognosis, compared with other origins of BTC (i.e. perihilar or distal cholangiocarcinoma or gallbladder cancer) [4]. Moreover, locally-advanced and metastatic BTC are frequently pooled in the same studies as advanced BTC. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - July 6, 2021 Category: Cancer & Oncology Authors: Julien Edeline, Angela Lamarca, Mair éad G McNamara, Timothy Jacobs, Richard A Hubner, Dan Palmer, Bas Groot Koerkamp, Philip Johnson, Boris Guiu, Juan W Valle Source Type: research

Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis
The phenomenon of receptor conversion during progression from early to metastatic breast cancer (BC) is well-described [1 –5]. This observation underscores the need to obtain metastatic biopsies, since they lead to changes in management in approximately 15-20% of patients [4–6]. As a result of the potential clinical validity and utility, obtaining a metastatic biopsy should be considered in line with contemporary g uidelines [7,8]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 30, 2021 Category: Cancer & Oncology Authors: Caroline Boman, Ioannis Zerdes, Kira M årtensson, Jonas Bergh, Theodoros Foukakis, Antonios Valachis, Alexios Matikas Source Type: research

First line treatment of BRAF mutated advanced melanoma: does one size fit all?
In the last decade, the development of novel treatment strategies has revolutionized the prognosis of patients affected by BRAF V600 mutation-positive metastatic melanoma[1 –3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 18, 2021 Category: Cancer & Oncology Authors: Giugliano Federica, Crimini Edoardo, Tarantino Paolo, Zagami Paola, Uliano Jacopo, Corti Chiara, Dario Trapani, Giuseppe Curigliano, Paolo A. Ascierto Tags: Anti-tumour Treatment Source Type: research

De-Escalating Adjuvant Therapies in Older Patients with Lower Risk Estrogen Receptor-Positive Breast Cancer Treated with Breast-Conserving Surgery: A Systematic Review and Meta-analysis
While the average age of diagnosis of breast cancer is 62 years, over 30% of patients are 70 years or older[1,2]. The incidence of breast cancer in older patients continues to rise and the global incidence in women ≥70 years is expected to double by 2040, from 445,081 to 908,119[3]. The use of adjuvant therapies in older patients is challenging due to a higher incidence of co-morbidities and functional decline, which increases the risk of treatment-related side effects and death due to non-cancer causes. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 18, 2021 Category: Cancer & Oncology Authors: Marie-France Savard, Mark Clemons, Brian Hutton, Meshari Jemaan Alzahrani, Jean-Michel Caudrelier, Lisa Vandermeer, Michelle Liu, Deanna Saunders, Marta Sienkiewicz, Carol Stober, Katherine Cole, Risa Shorr, Angel Arnaout, Lynn Chang Tags: Systematic or Meta-analysis Studies Source Type: research

Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 17, 2021 Category: Cancer & Oncology Source Type: research

A Systematic Review of HER2 Blockade for the Curative Treatment of Gastroesophageal Adenocarcinoma: Successes Achieved and Opportunities Ahead
Over one million cancer related deaths are attributable to esophageal and gastric cancer worldwide annually, ranking third and sixth as most frequent causes of global cancer mortality. [1] Neoadjuvant chemoradiotherapy (nCRT) is commonly used for the treatment of patients with esophageal adenocarcinoma (EAC), while perioperative chemotherapy is often administered to patients with gastric cancer. [1,2] Notwithstanding the benefit gained with multimodality treatment in both cancer types, the prognosis remains dismal with a high distant relapse rate following surgery.[1] Optimization of treatment is thus urgently needed. (Sou...
Source: Cancer Treatment Reviews - June 15, 2021 Category: Cancer & Oncology Authors: Charlotte I. Stroes, Tom van den Ende, Sarah Derks, Hanneke W.M. van Laarhoven Tags: Anti-tumour Treatment Source Type: research

Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: new reality with new challenges
Malignant pleural mesothelioma (MPM) is a rare and orphan thoracic malignancy, accounting for 2.1 cases per 100,000 people per year, and including epithelioid, sarcomatoid and biphasic histologic subtypes [1]. MPM is usually diagnosed at advanced stages due to the absence of early symptoms, and the diffuse nature of the disease combined with lack of sensitivity to chemotherapy may reduce the options for radical-curative approaches. While we are witnessing years of exciting progress for patients with advanced lung cancer, limited therapeutic improvements have been made in unresectable MPM since the approval of platinum-peme...
Source: Cancer Treatment Reviews - June 15, 2021 Category: Cancer & Oncology Authors: Kaushal Parikh, Lizza E. L. Hendriks, Paolo Bironzo, Jordi Remon Tags: Tumour Review Source Type: research

Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
Immunotherapy is revolutionizing the treatment of kidney cancer [1]. In recent years, immune checkpoint inhibitors (ICIs) have been developed and immune-combination therapies have dramatically changed the landscape of first-line treatment in metastatic renal cell carcinoma (mRCC) [2]. Indeed, the armamentarium of systemic therapy available in the first-line is governed by combination therapies, including programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) inhibitors [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 12, 2021 Category: Cancer & Oncology Authors: Keiichiro Mori, Benjamin Pradere, Fahad Quhal, Satoshi Katayama, Hadi Mostafaei, Ekaterina Laukhtina, Victor M. Schuettfort, David D'Andrea, Shin Egawa, Karim Bensalah, Manuela Schmidinger, Thomas Powles, Shahrokh F. Shariat Tags: Systematic or Meta-analysis Studies Source Type: research

Patient-Centric Decision Framework for Treatment Alterations in Patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of several commonly used classes of drugs including the taxanes (e.g., paclitaxel, docetaxel), platinums (e.g., oxaliplatin, cisplatin), vinca alkaloids (e.g., vincristine), and other anti-cancer agents including bortezomib. Some neurotoxic drugs cause an acute neuropathy that typically peaks 3-4 days after infusion and improves before the next dose[1] without necessitating treatment alteration. Chronic CIPN symptoms, the focus of the current review and heretofore referred to as CIPN, differ between neurotoxic chemotherapy agents but are genera...
Source: Cancer Treatment Reviews - June 8, 2021 Category: Cancer & Oncology Authors: Daniel L Hertz, Daniel S Childs, Susanna B. Park, Sara Faithfull, Yu Ke, Nadeen T Ali, Sheila Marie McGlown, Alexandre Chan, Lisa Grech, Charles L. Loprinzi, Kathryn J. Ruddy, Maryam Lustberg Tags: General and Supportive Care Source Type: research

The Promise of Bispecific antibodies: Clinical applications and challenges
In recent years, we have witnessed emergence of promising therapies such as immune checkpoint inhibitors which have revolutionized cancer treatment. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - June 3, 2021 Category: Cancer & Oncology Authors: Sun Min Lim, Kyoung-Ho Pyo, Ross A Soo, Byoung Chul Cho Tags: New Drugs Source Type: research

Complete response and Renal cell carcinoma in the Immunotherapy era: The paradox of good news
Renal cell carcinoma (RCC) is one of the most common urological cancers and the most frequent kidney solid tumor, being the clear cell RCC (ccRCC) the most frequent histological subtype (1). Survival outcomes of metastatic RCC (mRCC) have improved greatly during the last two decades with the advent of vascular endothelial growth factor-tyrosine kinase inhibitors (antiangiogenic agents, AA) and the incorporation of immune-checkpoint inhibitors (ICI) into the treatment landscape during the last 5 years (2,3). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 31, 2021 Category: Cancer & Oncology Authors: Francisco Zambrana, Lucia Carril-Ajuria, Alfonso G ómez de Liaño, Nieves Martinez Chanza, Ray Manneh, Daniel Castellano, Guillermo de Velasco Tags: Hot Topic Source Type: research

Adenocarcinoma Spectrum Lesions of the Lung: Detection, Pathology and Treatment Strategies
Worldwide, lung cancer outcomes remain poor. Lung cancer is often asymptomatic in its early stages therefore many patients present with advanced stage disease for which treatment with curative intent is often not possible. Lung cancer has the mortality rate of all cancers, responsible for 2.09 million deaths globally per annum[1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 28, 2021 Category: Cancer & Oncology Authors: L Succony, DM Rassl, AP Barker, FM McCaughan, RC Rintoul Tags: Tumour Review Source Type: research

NRAS mutant melanoma: towards better therapies
Cutaneous melanoma is a highly aggressive malignancy with a growing incidence accounting for around 290 000 cases (1.6%) of all newly diagnosed cancers worldwide and more than 60 000 deaths in 2018 [1,2]. Exogenous and endogenous risk factors cause malignant transformation of melanocytes, which are neural crest-derived and melanin-producing cells [2-4]. Exposure to ultraviolet (UV) radiation and a history of sunburns are the main carcinogens responsible for the onset of melanoma and other skin cancers, causing the highest tumor mutational burden (TMB) in somatic cells of all cancer types (median TMB of melanoma 14.4 mutati...
Source: Cancer Treatment Reviews - May 28, 2021 Category: Cancer & Oncology Authors: Tijana Randic, Ines Kozar, Christiane Margue, Jochen Utikal, Stephanie Kreis Tags: Anti-tumour Treatment Source Type: research

Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 26, 2021 Category: Cancer & Oncology Source Type: research

Breast reconstruction and radiation therapy: an expert Delphi Consensus statements and critical review
Breast cancer is the most common cause of cancer-related deaths for women worldwide with an overall increasing trend of prevalence and mortality rate [1,2]. Breast conserving surgery (BCS) plus radiation therapy (RT) or mastectomy have shown comparable oncological outcomes in early-stage breast cancer and are considered standard of care treatment to be offered to patients based on the specific disease presentation [3,4]. Although both interventions are valid options, mastectomy should not be regarded as equal to breast conservation [5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 26, 2021 Category: Cancer & Oncology Authors: Icro Meattini, Carlotta Becherini, Marco Bernini, Elisabetta Bonzano, Carmen Criscitiello, Fiorenza De Rose, Maria Carmen De Santis, Antonella Fontana, Pierfrancesco Franco, Oreste Davide Gentilini, Lorenzo Livi, Bruno Meduri, Silvana Parisi, Nadia Pasine Tags: Tumour Review Source Type: research

Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer
Cervical cancer is the number one cause of gynecological cancer death worldwide[1]. It is the fourth most frequent cancer in women globally, ranking after breast cancer (2 ·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million)[2]. It is estimated that 604,127 patients were diagnosed with the disease worldwide in 2020[1].Fig 1. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 21, 2021 Category: Cancer & Oncology Authors: F.J. Crowley, R.E. O'Cearbhaill, D.C. Collins Tags: Anti-tumour Treatment Source Type: research

Treatment breaks in first line treatment of advanced colorectal cancer: an individual patient data meta-analysis
Controversy continues regarding the necessity of maintenance therapy in advanced (metastatic) colorectal cancer. Historically, when treatment options were limited, 5FU was continued until disease progression. The introduction of oxaliplatin, with its cumulative neurotoxicity, raised the necessity of interrupting oxaliplatin therapy after a limited exposure to avoid worsening neuropathy. The clinical benefit of continuing systemic anti-cancer therapy is a balance between improved disease control and the reassurance of ongoing therapy on one hand versus ongoing and worsening toxicity and fatigue, repeated hospital visits (in...
Source: Cancer Treatment Reviews - May 19, 2021 Category: Cancer & Oncology Authors: Richard Adams, Kaitlyn Goey, Benoist Chibaudel, Miriam Koopman, Cornelis Punt, Dirk Arnold, Axel Hinke, Susanna Hegewisch-Becker, Aimery de Gramont, Roberto Labianca, Eduardo Diaz Rubio, Kjell Magne Tveit, Harpreet Wasan, Richard Kaplan, Louise Brown, Tim Tags: Systematic or Meta-analysis Studies Source Type: research

Checkpoints inhibitors in Metastatic Papillary Renal Cell Carcinoma
Papillary Renal Cell Carcinoma (pRCC) is the second most common RCC subtype and accounts for up 15% of all RCC1,2. Historically, pRCC has been associated with adverse outcomes compared to more common clear-cell tumors (ccRCC), mainly when metastatic, consistent with their categorization in non-clear cell RCC (nccRCC) encompassing aggressive and rare RCC subtypes3 –5. The International mRCC Database Consortium (IMDC) prognostic model was effective in stratifying patients with mpRCC, like patients with mccRCC, into favorable-, intermediate-, and poor-risk outcomes6,7. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 19, 2021 Category: Cancer & Oncology Authors: M. de Vries-Brilland, D.F. McDermott, C. Su árez, T. Powles, M. Gross-Goupil, A. Ravaud, R. Flippot, B. Escudier, L. Albigès Tags: Anti-tumour Treatment Source Type: research

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
The HER2-positive early breast cancer (EBC) treatment landscape evolved steadily over two decades [1]. Pivotal adjuvant trials [2-6] transformed standards-of-care, catalysing transition from chemotherapy to chemotherapy-plus-trastuzumab (significantly improving disease-free/overall survival [DFS/OS]). Neoadjuvant treatment opened two major avenues: increased pathological complete response (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 19, 2021 Category: Cancer & Oncology Authors: Christian Jackisch, Patricia Cortazar, Charles E. Geyer Jr, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart Tags: Anti-tumour Treatment Source Type: research

Recent advancements of antiangiogenic combination therapies in ovarian cancer
Ovarian cancer is the most lethal gynecological malignancy [1], responsible for nearly 5% of all cancer deaths despite the fact that it only accounts for 2.5% of all malignancies in women [2]. The disease presents at late stages in most cases and ultimately proves fatal to over 75% of those diagnosed with advanced tumors [3], with 70-80% of patients developing a relapse after upfront surgical debulking and chemotherapy [4]. The critical unmet need for more effective therapy has therefore spurred on the development of a more tailored and precision-based medicine. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 18, 2021 Category: Cancer & Oncology Authors: Daniel An, Susana Banerjee, Jung-Min Lee Tags: Anti-tumour Treatment Source Type: research

Turning tumors from cold to inflamed to improve immunotherapy response
Immunotherapy with checkpoint inhibitors (CPI) has profoundly changed the landscape of treatment in Oncology over the last decade by providing outstanding durable responses and potential long term remission in a significant proportion of patients[1 –3] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 18, 2021 Category: Cancer & Oncology Authors: C.L. Gerard, J. Delyon, A. Wicky, K. Homicsko, Michel A. Cuendet, O. Michielin Tags: Anti-tumour Treatment Source Type: research

Precision medicine in breast cancer: From clinical trials to clinical practice
Breast cancer (BC) is the most common cancer in women and, despite the undeniable improvements in the outcome of these patients obtained in the last decade, the discovery and the validation of new actionable molecular targets represent a priority. ESCAT permits to rank molecular alterations in different classes according to their evidence of actionability in a specific cancer type, assisting clinicians in their therapeutical decisions. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 11, 2021 Category: Cancer & Oncology Authors: Edoardo Crimini, Matteo Repetto, Philippe Aftimos, Andrea Botticelli, Paolo Marchetti, Giuseppe Curigliano Tags: Anti-tumour Treatment Source Type: research

Neoadjuvant approach as a platform for treatment personalization: focus on her2-positive and triple-negative breast cancer
Breast cancer (BC) represents the most frequently diagnosed tumor in women worldwide[1]. Systemic treatments for early-BC (EBC) have been historically administered in the adjuvant setting, however, in the last decades, the strategy of administering systemic therapy before surgery – in the so-called neoadjuvant setting – has been increasingly adopted, in order to expand locoregional treatment (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 11, 2021 Category: Cancer & Oncology Authors: Federica Miglietta, Maria Vittoria Dieci, Gaia Griguolo, Valentina Guarneri Tags: Hot Topic Source Type: research

Precision medicine inbreast cancer: from clinical trials to clinical practice
breast cancer (BC) is the most common cancer in women and, despite the undeniable improvements in the outcome of these patients obtained in the last decade, the discovery and the validation of new actionable molecular targets represent a priority. ESCAT permits to rank molecular alterations in different classes according to their evidence of actionability in a specific cancer type, assisting clinicians in their therapeutical decisions.Main: ERBB2, PIK3CA and germline BRCA1/2 alterations are biomarkers prospectively validated in BC, driving the selection of targeted therapies, and are therefore classified in the highest lev...
Source: Cancer Treatment Reviews - May 11, 2021 Category: Cancer & Oncology Authors: Edoardo Crimini, Matteo Repetto, Philippe Aftimos, Andrea Botticelli, Paolo Marchetti, Giuseppe Curigliano Tags: Anti-tumour Treatment Source Type: research

Cabozantinib: An Evolving Therapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) accounts for 90% of liver neoplasms and is an increasing global health burden [1-3]. While incidence and mortality rates are declining for cancer overall, they have been rising>2% annually over the past decade for liver cancer [4-7]. Despite therapeutic advances (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 11, 2021 Category: Cancer & Oncology Authors: Anthony B. El-Khoueiry, Diana L. Hanna, Josep Llovet, Robin Kate Kelley Tags: Anti-tumour Treatment Source Type: research

Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination
As the world embarks on mass vaccination for COVID-19, we are beginning to encounter unintended dilemmas in imaging oncology patients; particularly with regards to 18-fluorodeoxyglucose PET/CT (FDG PET/CT). In some cases, vaccine-related lymphadenopathy and FDG uptake on FDG PET/CT can mimic cancer and lead to confounding imaging results. Many of these cases of confusing results can be avoided by coordination of vaccination with planned imaging and avoiding the sequence of imaging being performed shortly after vaccination. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 10, 2021 Category: Cancer & Oncology Authors: Lacey J. McIntosh, Max P. Rosen, Kriti Mittal, Giles F. Whalen, Venu G. Bathini, Tasneem Ali, Kathryn L. Edmiston, William V. Walsh, Jonathan M. Gerber Tags: Hot Topic Source Type: research

Coordination and optimization of PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination
As the world embarks on mass vaccination for COVID-19, we are beginning to encounter unintended dilemmas in imaging oncology patients; particularly with regards to 18-fluorodeoxyglucose PET/CT (FDG PET/CT). In some cases, vaccine-related lymphadenopathy and FDG uptake on FDG PET/CT can mimic cancer and lead to confounding imaging results. Many of these cases of confusing results can be avoided by coordination of vaccination with planned imaging and avoiding the sequence of imaging being performed shortly after vaccination. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 10, 2021 Category: Cancer & Oncology Authors: Lacey J. McIntosh, Max P. Rosen, Kriti Mittal, Giles F. Whalen, Venu G. Bathini, Tasneem Ali, Kathryn L. Edmiston, William V. Walsh, Jonathan M. Gerber Tags: Hot Topic Source Type: research

Understanding the Immuno-biology of Oesophageal Adenocarcinoma: Towards Improved Therapeutic Approaches
Oesophageal adenocarcinoma (OAC) is a lethal cancer with a rising incidence globally [1]. Although oesophageal squamous cell carcinoma (OSCC) remains the dominant subtype worldwide due to its predominance across the “oesophageal cancer belt” through China, Central Asia, and Northern Iran as well as Eastern Africa, the incidence of OAC is rising in these populations also [2, 3]. The main risk factors for OAC include advancing age, male sex, obesity, and gastro-oesophageal reflux disease (GORD), and changes i n these epidemiological risk factors across both Western populations and through the oesophageal cancer b...
Source: Cancer Treatment Reviews - May 6, 2021 Category: Cancer & Oncology Authors: James M. Lonie, Andrew P. Barbour, Riccardo Dolcetti Tags: Tumour Review Source Type: research

Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone
Recent advances in mCRC treatment (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - May 3, 2021 Category: Cancer & Oncology Authors: Bengt Glimelius, Sebastian Stintzing, John Marshall, Takayuki Yoshino, Aimery de Gramont Tags: New Drugs Source Type: research

Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 28, 2021 Category: Cancer & Oncology Source Type: research

Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: a systematic review
In order to develop new, efficacious therapies against cancer, it is necessary to conduct early phase clinical trials: the first step in testing new compounds in humans. These trials are generally conducted in patients with advanced cancer for whom standard treatment is not or no longer an option. The main goal of early phase (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 28, 2021 Category: Cancer & Oncology Authors: Liza G.G. van Lent MA, Lea J. Jabbarian, Jelle van Gurp, Jeroen Hasselaar, Martijn P. Lolkema, Julia C.M. van Weert, Carin C.D. van der Rijt, Maja J.A. de Jonge Tags: Systematic or Meta-analysis Studies Source Type: research

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi Consensus
Prostate cancer (PCa) is the second most frequent cancer diagnosis in men and the fifth leading cause of death worldwide 1. Nowadays, the increased prostate specific antigen (PSA) surveillance and new imaging tools such as multiparametric magnetic resonance imaging (mp-MRI) have significantly improved the detection of clinically relevant disease. Therefore, PCa is nowadays diagnosed at a relatively younger age, and the patients have consequently a longer lifetime and a higher risk of developing recurrence after the first treatment of the primary tumour. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 19, 2021 Category: Cancer & Oncology Authors: Barbara A. Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, Simone Giovanni Gugliandolo, Dario Zerini, Federica Corso, Sara Gandini, Filippo Alongi, Alberto Bossi, Philip Cornford, Berardino De Bari, Val érie Fonteyne, Peter Hoskin, Bradley R. Pieters, Tags: Hot Topic Source Type: research

Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines
In multidisciplinary treatment of cancer in children and adolescents and young adults (AYAs), radiotherapy plays an important role as local treatment, but may also be closely related to long-term adverse events, including second cancer. Radiotherapy using proton beam therapy (PBT) is likely to reduce risks for growth and development disorders, endocrine dysfunction, reduced fertility and second cancer in children and AYAs because of its characteristic dose distribution of a decreased dose and volume in normal organs and maintenance of efficacy against the tumor. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 16, 2021 Category: Cancer & Oncology Authors: Masashi Mizumoto, Hiroshi Fuji, Mitsuru Miyachi, Toshinori Soejima, Tetsuya Yamamoto, Norihiro Aibe, Yusuke Demizu, Hiromitsu Iwata, Takayuki Hashimoto, Atsushi Motegi, Atsufumi Kawamura, Keita Terashima, Takashi Fukushima, Tomohei Nakao, Akinori Takada, Tags: Anti-tumour Treatment Source Type: research

Corrigendum to “Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis” [Cancer Treatm. Rev. 93 (2021) 102141]
The authors regret minor errors in the manuscript. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 12, 2021 Category: Cancer & Oncology Authors: Jonathan Strosberg, Oscar Leeuwenkamp, Mohd. Kashif Siddiqui Tags: Corrigendum Source Type: research

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
There has been a growing emphasis on driving up quality in cancer organisations given variations in outcomes in Europe. The European Cancer Concord (ECC), a partnership of patients, advocates and cancer (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 12, 2021 Category: Cancer & Oncology Authors: Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Gra ça Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferollà, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzil Tags: Systematic or Meta-analysis Studies Source Type: research

Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives
Renal cell carcinoma (RCC) constitutes the twelfth most common cancer worldwide, accounting for 3% of all adult malignancies [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 12, 2021 Category: Cancer & Oncology Authors: Mathieu Larroquette, Florent Peyraud, Charlotte Domblides, F élix Lefort, Jean-Christophe Bernhard, Alain Ravaud, Marine Gross-Goupil Tags: Anti-tumour Treatment Source Type: research

Benefit of Adjuvant Chemotherapy in Patients with Lobular Breast Cancer: a Systematic Review of the Literature and Metanalysis
Invasive lobular carcinoma is the second most commonly reported histology type of breast cancer (BC), after ductal carcinoma, accounting for 10-15% of new diagnoses. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 8, 2021 Category: Cancer & Oncology Authors: D Trapani, S Gandini, C Corti, E Crimini, F Bellerba, I Minchella, C Criscitiello, Paolo Tarantino, G Curigliano Tags: Systematic or Meta-analysis Studies Source Type: research

Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data
Renal cell carcinoma (RCC) affects almost 300,000 people worldwide each year and is responsible for more than 100,000 deaths annually. Understanding of RCC continues to rapidly evolve as new subtypes emerge, each characterized by distinct genomic and molecular alterations and variable responses to treatment, redefining the histological subtypes of kidney cancers [1]. In 2016, the revised World Health Organisation (WHO) renal tumor classification was published [2] to include these new rare renal tumor entities, however, the classification of some histological subtypes, such as the eosinophilic/oncocytic cell tumor group, is...
Source: Cancer Treatment Reviews - April 8, 2021 Category: Cancer & Oncology Authors: Philippe Barthelemy, Nathalie Rioux-Leclercq, Constance Thibault, Carolina Saldana, Delphine Borchiellini, Christine Chevreau, Isabelle Desmoulins, Aur élien Gobert, Werner Hilgers, Ahmed Khalil, Nathalie Lemoine, Friederike Schlürmann-Constans, Sylvie Tags: Tumour Review Source Type: research

Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
An enigmatic entity, cancer of unknown primary (CUP), has evolved alongside the development of modern oncology. The first mention of cancer with “unknown primary” dates back to 1946 [1]. Since that time, a shift in the definition and diagnosis occurred, associated with the emergence of ever more sophisticated diagnostic tools which aim to trace biological and molecular similarities to the elusive, possibly dormant or regressed, primary [ 2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 5, 2021 Category: Cancer & Oncology Authors: Timoth ée Olivier, Eugenio Fernandez, Intidhar Labidi-Galy, Pierre-Yves Dietrich, Veronica Rodriguez-Bravo, Giulia Baciarello, Karim Fizazi, Anna Patrikidou Tags: Tumour Review Source Type: research

Redefining Cancer Of Unknown Primary: Is Precision Medicine Really Shifting The Paradigm ?
An enigmatic entity, cancer of unknown primary (CUP), has evolved alongside the development of modern oncology. The first mention of cancer with “unknown primary” dates back to 1946 [1]. Since that time, a shift in the definition and diagnosis occurred, associated with the emergence of ever more sophisticated diagnostic tools which aim to trace biological and molecular similarities to the elusive, possibly dormant or regressed, primary [ 2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 5, 2021 Category: Cancer & Oncology Authors: Timoth ée Olivier, Eugenio Fernandez, Intidhar Labidi-Galy, Pierre-Yves Dietrich, Veronica Rodriguez-Bravo, Giulia Baciarello, Karim Fizazi, Anna Patrikidou Tags: Tumour Review Source Type: research

Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - April 1, 2021 Category: Cancer & Oncology Source Type: research

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis of individual patients ’ data from 3 phase III studies
CRC is the 3rd most commonly occurring cancer and the second cause of cancer-related death in the worldwide overall population (1 https://www.who.int/news-room/fact-sheets/detail/cancer). In the last decade the management of mCRC patients has notably improved. Optimizing molecular and clinical selection of mCRC patients, maximizing medical treatments (both chemotherapy, biological drugs and immunotherapy) and their combination with locoregional approaches (surgery, radiotherapy, radiofrequency etc.) has allowed to achieve median survivals of more than 30 months2,3. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 30, 2021 Category: Cancer & Oncology Authors: Lisa Salvatore, Emilio Bria, Isabella Sperduti, Axel Hinke, Susanna Hegewisch-Becker, Thomas Aparicio, Karine Le Malicot PhD, Val érie Boige, Dieter Koeberle, Daniela Baertschi, Daniel Dietrich, Giampaolo Tortora, Dirk Arnold Tags: Systematic or Meta-analysis Studies Source Type: research

Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: combination immunotherapy
Head and neck cancers represent the sixth most common malignancy worldwide and are projected to cause approximately 54,000 new cases and 11,000 deaths in the US in 2021 [1]. Head and neck squamous cell carcinoma (HNSCC) accounts for 90% of all head and neck cancers. Most HNSCC patients are diagnosed with locally advanced disease [2,3]. Despite advances in multimodality approaches, more than 50% of patients with locally advanced disease relapse and the median overall survival (OS) for patients with recurrent/metastatic (R/M) disease is only 10-13 months [2-5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 24, 2021 Category: Cancer & Oncology Authors: Ioannis A. Vathiotis, Jennifer M. Johnson, Athanassios Argiris Tags: New Drugs Source Type: research

Blood biomarkers for differential diagnosis and early detection of pancreatic cancer
Pancreatic cancer is a major health problem. Globally, 458,918 new cases and 432,242 deaths of pancreatic cancer have been reported in 2018 [1]. Currently, pancreatic cancer is the fourth and seventh most frequent cause of cancer-related death in Western countries and China, respectively, and expected to become second to only lung cancer in Western Europe and North America by 2030 [2]. Despite decades of research and advancement in disease management, the overall 5-years survival remains low at 5-9% of patients. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 24, 2021 Category: Cancer & Oncology Authors: Fawaz N. Al-Shaheri, Mohamed S.S. Alhamdani, Andrea Bauer, Nathalia Giese, Markus W. B üchler, Thilo Hackert, Jörg D. Hoheisel Tags: Laboratory-Clinic Interface Source Type: research